Anti-Human CTLA-4 (Ipilimumab) - Fc Muted™

Contact us
Leinco Technologies
Product Code: LEI-LT1605
Product Group: Primary Antibodies
CodeSizePrice
LEI-LT1605-CustomCustomEnquire
Quantity:
LEI-LT1605-500ug500 ug£408.00
Quantity:
Prices exclude any Taxes / VAT

Overview

Host Type: Human
Antibody Isotype: Human IgG1κ
Antibody Clonality: Monoclonal
Antibody Clone: MDX-010
Regulatory Status: RUO
Target Species: Human
Applications:
  • Blocking
  • Enzyme-Linked Immunosorbent Assay (ELISA)
  • Flow Cytometry
  • Mass Cytometry (CyTOF)
Shipping:
2 - 8°C Wet Ice
Storage:
Functional grade biosimilar antibodies may be stored sterile as received at 2-8°C for up to one month. For longer term storage aseptically aliquot in working volumes without diluting and store at -80°C.?Avoid Repeated Freeze Thaw Cycles.

Further Information

Antigen Distribution:
CTLA4 is constitutively expressed in regulatory T cells.
Concentration:
? 5.0 mg/ml
Conjugate/Tag/Label:
Purified No Carrier Protein
Format:
This biosimilar antibody is aseptically packaged and formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.2 - 7.4 with no carrier protein, potassium, calcium or preservatives added. Due to inherent biochemical properties of antibodies, certain products may be prone to precipitation over time. Precipitation may be removed by aseptic centrifugation and/or filtration.
Formulation:
This biosimilar antibody is aseptically packaged and formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.2 - 7.4 with no carrier protein, potassium, calcium or preservatives added. Due to inherent biochemical properties of antibodies, certain products may be prone to precipitation over time. Precipitation may be removed by aseptic centrifugation and/or filtration.
Immunogen:
Human CTLA-4
Long Description:
Cytotoxic T-lymphocyte?associated antigen 4 (CTLA-4) is a protein receptor that serves as an immune checkpoint and down-regulates the immune system. CTLA-4 is constitutively expressed in regulatory T cells but is only upregulated in conventional T cells following activation. Many cancers, including Melanoma, are associated with CTLA-4 upregulation because the body?s ability to recognize and destroy cancer cells is hampered by an inhibitory mechanism. Ipilimumab targets CTLA-4 and works by turning off this inhibitory mechanism and, thus, enhances the body?s own immune response against cancer cells.?2 Emerging research suggests that combined blockade of PD-1 and CTLA-4, with Nivolumab and Ipilimumab respectively, could produce greater antitumor activity than blockade of either pathway alone.1 This cost-effective, research-grade Anti-Human CTLA-4 (Ipilimumab) utilizes the same variable regions from the therapeutic antibody Ipilimumab making it ideal for research projects.
NCBI Gene:
1493
Purity:
?95% monomer by analytical SEC
Target:
CTLA-4

References

1. Wolchok, JD. et al. (2013) N Engl J Med 369(2):122-33. 2. Soo, RA. et al. (2017) Lancet Oncol. 18(12):e731-e741. 3. Lipson, EJ. and Drake, CG. (2011) Clin Cancer Res 17(22):6958-62.